Dr. Mark Charest, LifeSci Partners, spent some time with us talking about a wide range of topics:
Some of the topics covered:
Is biotech finally coming out of the doldrums?
How has recent M&A compared to 2021 and 2022?
Is "creative destruction" going to continue with rates at these levels?
Will banking issues impact biotech?
Is the regulatory environment a headwind or a tailwind?
Why are firms seeming to "overpay" for acquisitions?
A quick 13-minute conversation definitely worth your time...